Hemato Oncology Testing Trends and Forecast
The future of the global hemato oncology testing market looks promising with opportunities in the hospital and academic & research institutes market. The global hemato oncology testing market is expected to reach an estimated $7.2 billion by 2030 with a CAGR of 14.5% from 2024 to 2030. The major drivers for this market are increasing the number of conferences on personalized medicine, rising rate of hematologic cancer, and growing number of privately run diagnostic facilities.Hemato Oncology Testing by Segment
The study includes a forecast for the global hemato oncology testing by technology, cancer type, product, end use, and region.Hemato Oncology Testing Market by Technology [Shipment Analysis by Value from 2018 to 2030]
- PCR
- IHC
- NGS
- Cytogenetics
- Others
Hemato Oncology Testing Market by Cancer Type [Shipment Analysis by Value from 2018 to 2030]
- Leukemia
- Lymphoma
- Myeloproliferative Neoplasms
- Other
Hemato Oncology Testing Market by Product [Shipment Analysis by Value from 2018 to 2030]
- Assay Kits and Reagents
- Services
Hemato Oncology Testing Market by End Use [Shipment Analysis by Value from 2018 to 2030]
- Hospitals
- Academic & Research Institutes
- Others
Hemato Oncology Testing Market by Region [Shipment Analysis by Value from 2018 to 2030]
- North America
- Europe
- Asia Pacific
- The Rest of the World
List of Hemato Oncology Testing Companies
Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies hemato oncology testing companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the hemato oncology testing companies profiled in this report include-- F. Hoffmann-La Roche
- Abbott
- EntroGen
- Qiagen
- Cepheid
- Thermo Fisher Scientific
- Bio-Rad Laboratories
- Illumina
- Amoy Diagnostics
- ArcherDX
Hemato Oncology Testing Market Insights
The publisher forecasts that service will remain the larger segment over the forecast period due to increasing public knowledge of various treatment options, including tailored medications.North America will remain the largest region over the forecast period due to the increased prevalence of multiple myeloma, lymphoma, and leukemia, along with the availability of cutting-edge medical facilities and healthcare, as well as the introduction of new technology.
Features of the Global Hemato Oncology Testing Market
- Market Size Estimates: Hemato oncology testing market size estimation in terms of value ($B).
- Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.
- Segmentation Analysis: Hemato oncology testing market size by various segments, such as by technology, cancer type, product, end use, and region in terms of value ($B).
- Regional Analysis: Hemato oncology testing market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
- Growth Opportunities: Analysis of growth opportunities in different technology, cancer type, product, end use, and regions for the hemato oncology testing market.
- Strategic Analysis: This includes M&A, new product development, and competitive landscape of the hemato oncology testing market.
- Analysis of competitive intensity of the industry based on Porter’s Five Forces model.
FAQ
Q1. What is the hemato oncology testing market size?Answer: The global hemato oncology testing market is expected to reach an estimated $7.2 billion by 2030.
Q2. What is the growth forecast for hemato oncology testing market?
Answer: The global hemato oncology testing market is expected to grow with a CAGR of 14.5% from 2024 to 2030.
Q3. What are the major drivers influencing the growth of the hemato oncology testing market?
Answer: The major drivers for this market are increasing the number of conferences on personalized medicine, rising rate of hematologic cancer, and growing number of privately run diagnostic facilities.
Q4. What are the major segments for hemato oncology testing market?
Answer: The future of the global hemato oncology testing market looks promising with opportunities in the hospital and academic & research institutes market.
Q5. Who are the key hemato oncology testing market companies?
Answer: Some of the key hemato oncology testing companies are as follows:
- F. Hoffmann-La Roche
- Abbott
- EntroGen
- Qiagen
- Cepheid
- Thermo Fisher Scientific
- Bio-Rad Laboratories
- Illumina
- Amoy Diagnostics
- ArcherDX
Answer: The publisher forecasts that service will remain the larger segment over the forecast period due to increasing public knowledge of various treatment options, including tailored medications.
Q7. In hemato oncology testing market, which region is expected to be the largest in next 5 years?
Answer: North America will remain the largest region over the forecast period due to the increased prevalence of multiple myeloma, lymphoma, and leukemia, along with the availability of cutting-edge medical facilities and healthcare, as well as the introduction of new technology.
Q.8 Do we receive customization in this report?
Answer: Yes,the publisher provides 10% customization without any additional cost.
This report answers following 11 key questions:
Q.1. What are some of the most promising, high-growth opportunities for the hemato oncology testing market by technology (PCR, IHC, NGS, cytogenetics, and others), cancer type (leukemia, lymphoma, myeloproliferative neoplasms, and other), product (assay kits and reagents and services), end use (hospitals, academic & research institutes, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?Q.2. Which segments will grow at a faster pace and why?
Q.3. Which region will grow at a faster pace and why?
Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
Q.5. What are the business risks and competitive threats in this market?
Q.6. What are the emerging trends in this market and the reasons behind them?
Q.7. What are some of the changing demands of customers in the market?
Q.8. What are the new developments in the market? Which companies are leading these developments?
Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Global Hemato Oncology Testing Market: Market Dynamics
3. Market Trends and Forecast Analysis from 2018 to 2030
4. Market Trends and Forecast Analysis by Region from 2018 to 2030
5. Competitor Analysis
6. Growth Opportunities and Strategic Analysis
7. Company Profiles of Leading Players
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- F. Hoffmann-La Roche
- Abbott
- EntroGen
- Qiagen
- Cepheid
- Thermo Fisher Scientific
- Bio-Rad Laboratories
Methodology
The analyst has been in the business of market research and management consulting since 2000 and has published over 600 market intelligence reports in various markets/applications and served over 1,000 clients worldwide. Each study is a culmination of four months of full-time effort performed by the analyst team. The analysts used the following sources for the creation and completion of this valuable report:
- In-depth interviews of the major players in the market
- Detailed secondary research from competitors’ financial statements and published data
- Extensive searches of published works, market, and database information pertaining to industry news, company press releases, and customer intentions
- A compilation of the experiences, judgments, and insights of professionals, who have analyzed and tracked the market over the years.
Extensive research and interviews are conducted in the supply chain of the market to estimate market share, market size, trends, drivers, challenges and forecasts.
Thus, the analyst compiles vast amounts of data from numerous sources, validates the integrity of that data, and performs a comprehensive analysis. The analyst then organizes the data, its findings, and insights into a concise report designed to support the strategic decision-making process.
LOADING...
